AMCP Statement on the Introduction of the PIE Act of 2022
Alexandria, Va., March 10, 2022 — AMCP applauds Congressman Brett Guthrie (R-KY-02) on the introduction of the Pre-approval Information Exchange (PIE) Act of 2022 (H.R. 7008). One of AMCP’s top federal priorities, the bipartisan PIE Act will create a statutory safe harbor for the proactive dissemination of certain clinical and economic information to health payers regarding new therapies or new indications of existing therapies not yet approved by the Food & Drug Administration.
AMCP CEO Susan Cantrell gave the below statement on the importance of this legislation:
“The PIE Act will help patients receive swift access to new treatments by empowering pharmaceutical manufacturers to provide truthful and non-misleading evidence to health payers ahead of FDA approval. This allows payers to incorporate new therapies into their formularies for the plan year in which approval is anticipated. Public payers like Medicare and Medicaid will especially benefit from PIE due to their limited authority to modify formularies during a plan year.”
“I encourage Members of Congress to co-sponsor and ultimately pass this important, bipartisan legislation and thank Representative Guthrie for his leadership.”
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org.